• V Dytrych, J Kuchar, D Ambroz, J Kunstyr, T Grus, J Lindner, A Linhart, and P Jansa.
• Bratisl Med J. 2020 Jan 1; 121 (5): 356-361.

ObjectivesTo compare clinical parameters and quality of life in patients with pulmonary arterial hypertension (PAH) at the time of diagnosis, at the time of LenusPro pump implantation and during intravenous treptostinil treatment.MethodsSeven patients with severe PAH treated with intravenous treptostinil via implantable LenusPro pumps were evaluated, including NYHA classification, six‑minute walking test, BNP and quality of life assessment using the EQ-5D-5L questionnaire before and after pump implantation.ResultsNo significant changes were observed in NYHA class and six‑minute walking distance test. There was however a significant improvement in the quality of life and a decrease in BNP levels. The mean EQ-5D-5L index assessed during subcutaneous treptostinil treatment was significantly worse when compared to that assessed during its intravenous application (0.39 ± 0.24 vs 0.78 ± 0.28, p ˂ 0.05); the same is true about the pain/discomfort dimension. Complications occurred, namely one nonfatal pneumothorax, one nonfatal hemothorax, and one event of nonfatal treptostinil intoxication after refilling.ConclusionsIn patients who do not tolerate subcutaneous treptostinil treatment, the use of the LenusPro implantable pump results in a significant improvement in quality of life with an acceptable safety profile (Tab. 2, Fig. 2, Ref. 19).

10 keywords...

hide…